1. Home
  2. ATNI vs CBIO Comparison

ATNI vs CBIO Comparison

Compare ATNI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$24.49

Market Cap

392.6M

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$11.18

Market Cap

340.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
CBIO
Founded
1987
2003
Country
United States
United States
Employees
N/A
44
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
392.6M
340.4M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ATNI
CBIO
Price
$24.49
$11.18
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
81.8K
162.2K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
4.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$729,075,000.00
N/A
Revenue This Year
$3.60
N/A
Revenue Next Year
$1.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$8.72
52 Week High
$30.45
$17.39

Technical Indicators

Market Signals
Indicator
ATNI
CBIO
Relative Strength Index (RSI) 41.81 47.95
Support Level $21.15 $10.45
Resistance Level $26.80 $13.37
Average True Range (ATR) 1.39 0.94
MACD -0.63 0.00
Stochastic Oscillator 19.84 20.03

Price Performance

Historical Comparison
ATNI
CBIO

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: